J
Javier San Martin
Researcher at Eli Lilly and Company
Publications - 30
Citations - 4949
Javier San Martin is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: X-linked hypophosphatemia & Osteomalacia. The author has an hindex of 16, co-authored 30 publications receiving 4046 citations. Previous affiliations of Javier San Martin include Kyowa Hakko Kirin Co., Ltd..
Papers
More filters
Journal ArticleDOI
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings,Javier San Martin,Michael R. McClung,Ethel S. Siris,Richard Eastell,Ian R. Reid,Pierre D. Delmas,Holly B. Zoog,M. Austin,Andrea Wang,Stepan Kutilek,Silvano Adami,Jose R. Zanchetta,Cesar Libanati,Suresh Siddhanti,Claus Christiansen +15 more
TL;DR: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis.
Journal ArticleDOI
Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass
Michael R. McClung,Javier San Martin,Paul D. Miller,Roberto Civitelli,Francisco Bandeira,Molly Omizo,David W. Donley,Gail P. Dalsky,Erik Fink Eriksen +8 more
TL;DR: Two distinct options for the management of osteoporosis lead to increases in BMD by opposite mechanisms of action on bone remodeling.
Journal ArticleDOI
Burosumab Therapy in Children with X-Linked Hypophosphatemia.
Thomas O. Carpenter,Michael P. Whyte,Erik A. Imel,Annemieke Boot,Wolfgang Högler,Agnès Linglart,Raja Padidela,William van’t Hoff,Meng Mao,Chao-Yin Chen,Alison Skrinar,Emil D. Kakkis,Javier San Martin,Anthony A. Portale +13 more
TL;DR: In this paper, an X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophophosphateemia and consequently rickets, osteomalacia.
Journal ArticleDOI
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
Tony M. Keaveny,David W. Donley,Paul F. Hoffmann,Bruce H. Mitlak,Emmett V. Glass,Javier San Martin +5 more
TL;DR: FE modeling was used to estimate the biomechanical effects of teriparatide and alendronate on lumbar vertebrae, which enhanced predicted vertebral strength by increasing average density.
Journal ArticleDOI
Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters
Monique E. Arlot,Pierre J. Meunier,Georges Boivin,Lillian Haddock,Juan Tamayo,Ricardo Correa-Rotter,Salomón Jasqui,David W. Donley,Gail P Dalsky,Javier San Martin,Erik Fink Eriksen +10 more
TL;DR: An 18‐month randomized double‐blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once‐daily teriparatide 20 μg with alendronate 10 mg on bone histomorphometry.